More recently, BACE1 activity has been associated with increased AD development risk [81], but current evidence remains inconsistent and limited by methodological heterogeneity: thus, BACE1 can not yet be considered a clinically actionable biomarker. Here, BACE1 is linked to Alzheimer disease.